SEC Tracker
Get the app
CCEL · XBRL financial data

Cryo-Cell International financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CCEL's year ends in late November)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Cost of goods and services sold2,076*2,1602,0252,1261,637*1,9851,8571,8011,734*1,6561,6771,613
Research and development444*503241194305*981326285*6610054
Selling, general and administrative5,393*4,3404,0214,1506,010*4,6384,2583,8765,448*5,0124,6183,779
Operating income (loss)(16,176)*8211,3921,390(122)*1,0561,4931,901(3,967)*7651,1972,194
Interest expense(169)*256329533745*495551538482*463442438
Other income (expense)0*0015*4131818*800
Income tax expense (benefit)(4,803)*2388163281,019*251219437(815)*23273555
Net income (loss)(11,190)*5566561,052(1,862)*283356749(3,817)*475551,270
Earnings per share, basic USD per share(1.35)*0.070.080.13(0.23)*0.030.040.09(0.47)*0.010.070.16
Earnings per share, diluted USD per share(1.36)*0.070.080.13(0.23)*0.030.040.09(0.48)*0.010.070.16
Weighted average shares, basic thousands of shares8,287*8,2788,1178,0628,066*8,0828,0808,0588,055*8,0558,0558,063
Weighted average shares, diluted thousands of shares8,216*8,3258,2328,1748,119*8,2008,1268,0747,876*8,0568,0558,065

Balance sheet

CSV

Fiscal quarters (CCEL's year ends in late November)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Cash and cash equivalents4062474691975612231372653192505071,426
Marketable securities5747321,0601,9292,9353,2564,2942,9562,9772,6502,6552,803
Accounts receivable6,5766,7276,8316,8747,3097,2126,9316,8336,8466,8166,9106,834
Inventory769755708731658730677655409357310534
Total current assets9,4539,45210,15710,66112,55512,50913,05311,67311,75811,07711,30413,172
Property and equipment, net20,99721,60522,16222,11821,89421,72521,39221,19921,03420,86820,66920,541
Right-of-use asset1,033958882897806714620907820722622529
Goodwill1,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,9411,941
Total assets61,22161,71162,56762,93464,67864,38164,43863,16961,72960,88560,70662,303
Accounts payable3,1752,9971,8282,0011,8822,7442,2412,6122,8713,3022,8472,421
Accrued liabilities5,1713,9173,2172,6815,8104,3372,6742,2854,2782,8872,9672,565
Total current liabilities20,86419,37019,44817,42321,60021,72221,75318,45219,79317,76415,93015,332
Lease liability, non-current852769672619505387265577475369261150
Total liabilities72,25272,04973,30872,49377,89479,03779,99878,00180,33479,28578,46478,697
Accumulated deficit(31,159)(30,603)(29,947)(28,895)(32,778)(34,515)(35,370)(34,621)(38,438)(38,391)(37,837)(36,566)
Total stockholders' equity(11,031)(10,338)(10,741)(9,559)(13,216)(14,656)(15,560)(14,831)(18,606)(18,400)(17,758)(16,395)
Total liabilities and equity61,22161,71162,56762,93464,67864,38164,43863,16961,72960,88560,70662,303
Common shares outstanding (cover page) thousands of shares8,2878,1048,0628,0628,0828,0828,0578,0558,0558,0558,0638,063

Cash flows

CSV

Fiscal quarters (CCEL's year ends in late November)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Net income (loss)(11,190)*5566561,052(1,862)*283356749(3,817)*475551,270
Stock-based compensation175*307178*146*150*29740*37*43*15965*93*
Depreciation and amortization336*86112*247*249*248250*244*243*244244*241*
Net cash from operating activities3,344*(357)1,773*2,437*2,157*954707*2,537*1,281*6521,846*1,142*
Purchases of property and equipment1,715*4581,752*186*8*6262*39*67*6733*102*
Net cash from investing activities(1,982)*(341)(2,755)*(666)*(1,116)*(287)(1,503)*1,105*(290)*1935*(181)*
Share repurchases0*1701,237*16*0*089*81*0*——0*
Dividends paidyear only00*0*2,021*2,0211,211*0*0*00*0*
Net cash from financing activities(1,541)*5391,203*(2,043)*(678)*(1,004)710*(3,514)*(937)*(740)(1,623)*(43)*

Compare with peers

SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cryo Cell International1,4267,8241,142*8.1M— 10-QAug 31, 2026
Elite Health Systems1,3021,310(1,353)*28.5M1.0 quarters 10-QJun 30, 2026
Mangoceuticals22969(261)*21.6M0.9 quarters 10-QJun 30, 2026
BioRestorative Therapies3,11323(3,808)25.5M0.9 quarters 10-QMar 31, 2026
Marpai1384,166(4,099)*26.8M0.0 quarters 10-QJun 30, 2026
Quipt Home Medical10,54380,9968,94144.5M— 10-QDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.